Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › About Us › Our Staff › staff reporter

staff reporter

Email
[email protected]

Articles Authored by staff reporter

Apr 06, 2020

Myriad Genetics BRCA Test to be Reimbursed in Japan

The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.

Apr 03, 2020

NOTCH Mutations Potentially Predictive for Immunotherapy Response in Lung Cancer

Deleterious NOTCH mutations may predict more favorable immune checkpoint responses in lung cancer patients without EGFR or ALK mutations.

Apr 03, 2020

Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.

Apr 02, 2020

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

Following a positive interim analysis of the Phase III OVAL trial, Japan-based NanoCarrier plans to open trial sites for VBL Therapeutics' VB-111.

Apr 02, 2020

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

HER2-targeted bispecific antibody ZW25 will be used in combination with other drugs for HER2-positive breast cancer and gastroesophageal adenocarcinoma.

Apr 01, 2020

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Researchers found that TP53 mutations correlated with improved disease-free survival and overall survival in pancreatic cancer patients treated with gemcitabine following surgical resection.

Apr 01, 2020

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

A study evaluated data from a Phase I/II trial of Piqray combined with an aromatase inhibitor to find mechanisms of resistance hindering clinical benefit from the therapy.

Apr 01, 2020

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Top-line results from the first part of the Atalante 1 trial showed the company's investigational product Tedopi produced a 12-month survival rate of 46 percent.

Apr 01, 2020

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

A Phase II study suggests immune-related expression signatures and other immune markers may help find metastatic prostate cancer cases with better checkpoint blockade response.

Apr 01, 2020

Blueprint Medicines Advance Pralsetinib in Multiple RET-Mutant Indications

The company announced that it is planning to submit an NDA for the drug in RET-mutant medullary thyroid cancer.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.